Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Other Non Operating Income (2016 - 2025)

Jaguar Health (JAGX) has disclosed Other Non Operating Income for 11 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 18.64% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61000.0 through Dec 2025, down 95.1% year-over-year, with the annual reading at $43000.0 for FY2025, 96.55% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $1.9 million at Jaguar Health, up from -$94000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $1.9 million in Q4 2025, with the low at -$3.5 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is -$466894.7, with a median of -$70000.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income tumbled 6276.47% in 2022, then soared 2050.0% in 2024.
  • Over 5 years, Other Non Operating Income stood at -$20000.0 in 2021, then crashed by 8785.0% to -$1.8 million in 2022, then tumbled by 96.79% to -$3.5 million in 2023, then skyrocketed by 144.95% to $1.6 million in 2024, then grew by 18.64% to $1.9 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $1.9 million, -$94000.0, and -$1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.